Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | HTR2B | P41595 | 4/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750085 | 1.00 | KIF11 (0.42) | KIF11HTR2CHTR2AHTR2BCD274 | |
| SCHEMBL20835027 | 0.79 | TRPA1 (0.31) | HTR2B | |
| SCHEMBL21500484 | 0.78 | HTR2C (0.38) | KIF11HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL19406884 | 0.78 | HTR2C (0.38) | KIF11HTR2CHTR2AHTR2BCYP1A2 | |
| SCHEMBL31336038 | 0.78 | HTR2C (0.38) | KIF11HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL11325808 | 0.78 | PNMT (0.54) | KIF11HTR2CADRA2APNMTADRA2B | |
| SCHEMBL23771285 | 0.75 | HTR2C (0.43) | HTR2CHTR2B | |
| SCHEMBL11198207 | 0.75 | HTR2C (0.38) | KIF11HTR2CCYP1A2POLB | |
| SCHEMBL29750070 | 0.73 | CD44 (0.42) | KIF11HTR2CCYP1A2PNMTCD44 | |
| SCHEMBL5068782 | 0.73 | CD44 (0.42) | KIF11HTR2CCYP1A2PNMTCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-114920911-A | Method for producing polyisothianaphthene-based conductive polymer | 昭和电工株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-110121516-B | Method for producing polyisothianaphthene-based conductive polymer | 昭和电工株式会社 | 2022-07-01 | — | — | CN | disclosed |
| US-11183340-B2 | Method for manufacturing solid electrolytic capacitor | SHOWA DENKO K.K. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-11136432-B2 | Method for producing polyisothianaphthene-based electroconductive polymer | SHOWA DENKO K.K. (JP) | 2021-10-05 | — | — | US | disclosed |
| CN-110121757-B | Method for manufacturing solid electrolytic capacitor | 昭和电工株式会社 | 2021-09-14 | — | — | CN | disclosed |
| US-20200090874-A1 | METHOD FOR MANUFACTURING SOLID ELECTROLYTIC CAPACITOR | SHOWA DENKO K.K. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20190345287-A1 | METHOD FOR PRODUCING POLYISOTHIANAPHTHENE-BASED ELECTROCONDUCTIVE POLYMER | SHOWA DENKO K.K. (JP) | 2019-11-14 | — | — | US | disclosed |
| EP-3564290-A1 | METHOD FOR PRODUCING POLYISOTHIANAPHTHENE ELECTROCONDUCTIVE POLYMER | Showa Denko K.K. (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564976-A1 | METHOD FOR MANUFACTURING SOLID ELECTROLYTIC CAPACITOR | Showa Denko K.K. (JP) | 2019-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | KIF11 2235/4885HTR2C 1116/4885HTR2A 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.